Supplementary data from a Mendelian Randomization study investigating genetically proxied JAK inhibition associations with disease outcomes and adverse effects. The analysis utilized genetic data from the UK Biobank (361,194 participants) and FinnGen (453,733 participants). The dataset was authored by Yuping Zhang and last updated in March 2026.
Use Cases
- Validate genetic associations between TYK2 inhibition and psoriasis based on summary-data-based Mendelian Randomization (SMR) results.
- Explore hypothesis-generating signals for adverse events like pulmonary embolism and tuberculosis linked to JAK2 inhibition.
- Compare genetic evidence with clinical trial safety outcomes for JAK inhibitors in immune-mediated inflammatory diseases.
- Investigate associations between JAK/TYK2 inhibition and cancer risks, such as non-melanoma skin cancer and lung cancer.
Strengths
- Genetic data sourced from two large cohorts: UK Biobank (361,194 participants) and FinnGen (453,733 participants).
- Analysis includes associations with nine autoimmune skin diseases and twelve adverse outcomes.
- Results are supported by a systematic review of randomized controlled trials.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
- The dataset is 145.2 KB, indicating a limited scope likely containing summary statistics rather than raw genetic data.
Provenance
- Source
- figshare
- Collection Method
- Summary-data-based Mendelian Randomization (SMR) analysis complemented by a systematic review of RCTs.
- Freshness
- Last updated 2026-03-19 06:34:13